Coeptis Therapeutics (NASDAQ:ZSQR) Announces Earnings Results

Coeptis Therapeutics (NASDAQ:ZSQR) released its earnings results on Thursday. The company reported ($0.65) earnings per share (EPS) for the quarter, FiscalAI reports. The company had revenue of $0.11 million during the quarter. Coeptis Therapeutics had a negative net margin of 803.96% and a negative return on equity of 110.89%.

Coeptis Therapeutics Stock Down 6.0%

Shares of NASDAQ ZSQR opened at $9.25 on Friday. The company has a market capitalization of $57.54 million, a price-to-earnings ratio of -3.10 and a beta of -0.09. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.16 and a quick ratio of 4.16. The business has a 50-day moving average of $12.59 and a two-hundred day moving average of $13.69. Coeptis Therapeutics has a 1 year low of $6.80 and a 1 year high of $21.41.

Institutional Trading of Coeptis Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC lifted its holdings in Coeptis Therapeutics by 12.6% during the 4th quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock worth $600,000 after buying an additional 4,721 shares during the last quarter. State Street Corp lifted its holdings in Coeptis Therapeutics by 35.0% during the 4th quarter. State Street Corp now owns 26,830 shares of the company’s stock worth $382,000 after buying an additional 6,962 shares during the last quarter. Marshall Wace LLP purchased a new stake in Coeptis Therapeutics during the 4th quarter worth about $259,000. Yorkville Advisors Global LP purchased a new stake in Coeptis Therapeutics during the 3rd quarter worth about $140,000. Finally, Steward Partners Investment Advisory LLC lifted its holdings in Coeptis Therapeutics by 100.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock worth $71,000 after buying an additional 2,500 shares during the last quarter. 13.88% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Coeptis Therapeutics in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.